These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 27979961)

  • 41. Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
    Tbakhi A; Pettay J; Sreenan JJ; Abdel-Razeq H; Kalaycio M; Hoeltge G; Miller ML; Tubbs RR
    Am J Clin Pathol; 1998 Jan; 109(1):16-23. PubMed ID: 9426513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
    Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
    Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variant-specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.
    Kjaer L; Skov V; Andersen MT; Aggerholm A; Clair P; Gniot M; Soeby K; Udby L; Dorff MH; Hasselbalch H; Pallisgaard N
    Eur J Haematol; 2019 Jul; 103(1):26-34. PubMed ID: 30985947
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR.
    Jennings LJ; George D; Czech J; Yu M; Joseph L
    J Mol Diagn; 2014 Mar; 16(2):174-9. PubMed ID: 24389534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.
    Alikian M; Ellery P; Forbes M; Gerrard G; Kasperaviciute D; Sosinsky A; Mueller M; Whale AS; Milojkovic D; Apperley J; Huggett JF; Foroni L; Reid AG
    J Mol Diagn; 2016 Mar; 18(2):176-89. PubMed ID: 26857065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Detection of
    Ruan M; Zhang LL; Li YM; Li DY; Yuan ZY; Zheng ZZ; Zeng QS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1647-1656. PubMed ID: 38071041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.
    Jennings LJ; Smith FA; Halling KC; Persons DL; Kamel-Reid S;
    Arch Pathol Lab Med; 2012 Jan; 136(1):33-40. PubMed ID: 22208485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
    Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
    Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
    Lee YK; Lee DW; Kim YL; Lee S; Min CK; Kim YJ; Oh IH; Kim TG; Kim CC; Kim DW
    Int J Hematol; 2002 Aug; 76(2):180-5. PubMed ID: 12215018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.
    Foskett P; Gerrard G; Foroni L
    Methods Mol Biol; 2014; 1160():115-24. PubMed ID: 24740226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
    Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
    Moravcová J; Brdicka R
    Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia.
    Hessner MJ; Roth MS; Drobyski WR; Baxter-Lowe LA
    Genet Anal Tech Appl; 1994; 11(4):90-4. PubMed ID: 7857690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discontinuation of tyrosine kinase inhibitors based on
    Kim Y; Kim S; Lee JM; Ahn A; Yoo JW; Lee JW; Cho B; Chung NG; Kim Y; Kim M
    Front Pediatr; 2022; 10():928136. PubMed ID: 35967571
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R; Press RD
    Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.